MedPath

An open, multi-centre, non-comparative observational study to assess the safety and tolerability of Oxycodone hydrochloride injection 50 mg/mL as a subcutaneous infusion in subjects with severe cancer pain.

Conditions
Severe cancer pain
Registration Number
EUCTR2007-005101-21-GB
Lead Sponsor
Mundipharma Research Limited
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1. Male or female subjects aged 18 years and over, who have severe cancer pain.
2. Subjects who require a strong opioid by subcutaneous infusion to stabilise and manage their cancer pain effectively.
3. Subjects who have provided written informed consent.
4. Subjects who agree to their general practitioner being informed of their participation in the study.
5. Subjects who consent to processing of their study data according to the requirements of the UK Data Protection Act 1998.

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1. Subjects who are pregnant, lactating or in the investigators opinion are at risk of conceiving and are not using adequate contraception measures.
2. Subjects with known hypersensitivity (allergic reaction) to oxycodone, any other opioids or any of the excipients.
3. Subjects who are planned to receive chemotherapy during the study treatment period or are currently receiving continuous i.v. chemotherapy infusion.
4. Subjects with neutropenia, thrombocytopenia or coagulation disorders
5. Subjects with any contraindications to oxycodone as outlined in the Investigator Brochure or Summary Product Information sheet for oxycodone.
6. Subjects who are currently participating in another clinical research study involving a new chemical entity.
7. Subjects whom the investigator believes to be medically unfit to receive the study medication, or unsuitable for any other reason.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath